Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carol A Pollock

Showing results (141-150 of 168) with videos related to

Pageof 17
Sort By:
Scientific Reports|April 28, 2018
MitoQ supplementation prevent long-term impact of maternal smoking on renal development, oxidative stress and mitochondrial density in male mice offspringSuporn Sukjamnong, Yik Lung Chan, Razia Zakarya, et al.
Journal of the American Society of Nephrology : JASN|April 1, 2022
Roxadustat Versus Epoetin Alfa for Treating Anemia in Patients with Chronic Kidney Disease on Dialysis: Results from the Randomized Phase 3 ROCKIES StudySteven Fishbane, Carol A Pollock, Mohamed El-Shahawy, et al.
Current Medical Research and Opinion|June 21, 2008
A randomised, cross-over study comparing injection site pain with subcutaneous epoetin beta and subcutaneous darbepoetin alfa in patients with chronic kidney diseaseSimon D Roger, Michael G Suranyi, Rowan G Walker, et al.
JCI Insight|January 11, 2022
A single-domain i-body, AD-114, attenuates renal fibrosis through blockade of CXCR4Qinghua Cao, Chunling Huang, Hao Yi, et al.
Circulation|August 21, 2023
Cardiorenal Biomarkers, Canagliflozin, and Outcomes in Diabetic Kidney Disease: The CREDENCE TrialJames L Januzzi, Reza Mohebi, Yuxi Liu, et al.
Kidney International|December 14, 2012
Circulating bone morphogenetic protein-7 and transforming growth factor-β1 are better predictors of renal end points in patients with type 2 diabetes mellitusMuh Geot Wong, Vlado Perkovic, Mark Woodward, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|September 28, 2021
The IDEAL trial in Australia and New Zealand: clinical and economic impactKathryn B Dansie, Christopher E Davies, Rachael L Morton, et al.
Scientific Reports|September 16, 2021
Publisher Correction: Non-invasive assessment of exfoliated kidney cells extracted from urine using multispectral autofluorescence featuresSaabah B Mahbub, Long T Nguyen, Abbas Habibalahi, et al.
Scientific Reports|May 21, 2021
Non-invasive assessment of exfoliated kidney cells extracted from urine using multispectral autofluorescence featuresSaabah B Mahbub, Long T Nguyen, Abbas Habibalahi, et al.
Plos One|November 16, 2020
Rate of decline in residual kidney function pre and post peritoneal dialysis initiation: A post hoc analysis of the IDEAL studyIsabelle Ethier, Yeoungjee Cho, Carmel Hawley, et al.
Pageof 17

Showing results (141-150 of 168) with videos related to

Sort By:
Pageof 17
Scientific Reports|April 28, 2018
MitoQ supplementation prevent long-term impact of maternal smoking on renal development, oxidative stress and mitochondrial density in male mice offspringSuporn Sukjamnong, Yik Lung Chan, Razia Zakarya, et al.
Journal of the American Society of Nephrology : JASN|April 1, 2022
Roxadustat Versus Epoetin Alfa for Treating Anemia in Patients with Chronic Kidney Disease on Dialysis: Results from the Randomized Phase 3 ROCKIES StudySteven Fishbane, Carol A Pollock, Mohamed El-Shahawy, et al.
Current Medical Research and Opinion|June 21, 2008
A randomised, cross-over study comparing injection site pain with subcutaneous epoetin beta and subcutaneous darbepoetin alfa in patients with chronic kidney diseaseSimon D Roger, Michael G Suranyi, Rowan G Walker, et al.
JCI Insight|January 11, 2022
A single-domain i-body, AD-114, attenuates renal fibrosis through blockade of CXCR4Qinghua Cao, Chunling Huang, Hao Yi, et al.
Circulation|August 21, 2023
Cardiorenal Biomarkers, Canagliflozin, and Outcomes in Diabetic Kidney Disease: The CREDENCE TrialJames L Januzzi, Reza Mohebi, Yuxi Liu, et al.
Kidney International|December 14, 2012
Circulating bone morphogenetic protein-7 and transforming growth factor-β1 are better predictors of renal end points in patients with type 2 diabetes mellitusMuh Geot Wong, Vlado Perkovic, Mark Woodward, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|September 28, 2021
The IDEAL trial in Australia and New Zealand: clinical and economic impactKathryn B Dansie, Christopher E Davies, Rachael L Morton, et al.
Scientific Reports|September 16, 2021
Publisher Correction: Non-invasive assessment of exfoliated kidney cells extracted from urine using multispectral autofluorescence featuresSaabah B Mahbub, Long T Nguyen, Abbas Habibalahi, et al.
Scientific Reports|May 21, 2021
Non-invasive assessment of exfoliated kidney cells extracted from urine using multispectral autofluorescence featuresSaabah B Mahbub, Long T Nguyen, Abbas Habibalahi, et al.
Plos One|November 16, 2020
Rate of decline in residual kidney function pre and post peritoneal dialysis initiation: A post hoc analysis of the IDEAL studyIsabelle Ethier, Yeoungjee Cho, Carmel Hawley, et al.
Pageof 17